TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics


TRACON Pharmaceuticals, Inc. (TCON): $1.65

0.10 (+6.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TCON to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TCON Stock Price Chart Interactive Chart >

Price chart for TCON

TCON Price/Volume Stats

Current price $1.65 52-week high $2.90
Prev. close $1.55 52-week low $1.10
Day low $1.53 Volume 39,500
Day high $1.67 Avg. volume 72,607
50-day MA $1.62 Dividend yield N/A
200-day MA $1.67 Market Cap 39.31M

TRACON Pharmaceuticals, Inc. (TCON) Company Bio


Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.


TCON Latest News Stream


Event/Time News Detail
Loading, please wait...

TCON Latest Social Stream


Loading social stream, please wait...

View Full TCON Social Stream

Latest TCON News From Around the Web

Below are the latest news stories about TRACON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TCON as an investment opportunity.

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | March 14, 2023

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call. . During today’s call, we will be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, […]

Yahoo | March 10, 2023

Q4 2022 TRACON Pharmaceuticals Inc Earnings Call

Q4 2022 TRACON Pharmaceuticals Inc Earnings Call

Yahoo | March 9, 2023

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 P

Yahoo | March 8, 2023

TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In add

Yahoo | February 28, 2023

Read More 'TCON' Stories Here

TCON Price Returns

1-mo -2.37%
3-mo 26.44%
6-mo -7.30%
1-year -42.31%
3-year 42.24%
5-year -93.40%
YTD 10.74%
2022 -46.21%
2021 -76.32%
2020 400.00%
2019 -62.86%
2018 -81.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7025 seconds.